… received single doses of apixaban 5 mg intravenously on day 1 and 10 mg orally on day 3,
… Finally, participants received single doses of apixaban 5 mg intravenously and 10 mg orally …

… with apixaban. The trough and peak samples of these patients were tested for anti-Xa activity
with factor Xa-calibrated anti-Xa chromogenic analysis. The detected trough anti-Xa activity …

… Factor Xa (FXa), one of the enzymes and validated target for anticoagulation, regulates
the … The importance of oral FXa inhibitors like rivaroxaban, apixaban and edoxaban in …

… In summary, the reported studies in this manuscript clearly suggest that despite their
central action targeting factor Xa inhibition, the oral anti-Xa drugs exhibit markedly different …

… Three factor Xa inhibitors are currently indicated for use in nonvalvular … the factor Xa inhibitors
are administered orally. Rivaroxaban and edoxaban are dosed once daily while apixaban …

… the anti-Xa agents apixaban and rivaroxaban. This is important, given that since their release
for clinical use, utilisation of both anti-Xa … measure levels of apixaban and rivaroxaban in …

… Inclusion criteria included adults at least 18 years old who had received an anti-FXa inhibitor
(apixaban, rivaroxaban, edoxaban, or enoxaparin) within the past 18 hours at the time of …

… efficacy the novel anticoagulants are required. New agents like enoxaparin, apixaban and
… [1] Betrixaben is approved by FDA in class of clotting factor Xa inhibitor. Betrixaban became …

… apixaban showed an ability of aripazine to reverse the anti-factor Xa activity of direct
factor Xa inhibitors … NOAC including factor Xa inhibitors and direct thrombin inhibitors (dabigatran), …

… Likewise, in the ADOPT study, extended-duration thromboprophylaxis with apixaban failed
… , Inc) is a new, long-acting, oral, selective factor Xa (FXa) inhibitor that has demonstrated …